Nanobiotix

Biotech & Life Sciences · Paris, France · Founded 2003 · IPO 2012

Nanobiotix focuses on the development of nanomedicine solutions, specifically utilizing hafnium oxide nanoparticles to enhance the efficacy of radiotherapy in treating solid tumors. The company's core product, NBTXR3, is designed to be injected directly into tumors, where it amplifies the effects of radiation therapy, potentially improving treatment outcomes for patients with various types of cancer, including head and neck, liver, and soft tissue sarcomas. Operating in the oncology sector, Nanobiotix targets healthcare providers and institutions involved in cancer treatment. The business model revolves around the research, development, and commercialization of its proprietary nanoparticle technology, generating revenue through partnerships, licensing agreements, and direct sales to medical facilities. The company is actively involved in clinical trials and collaborates with academic and medical institutions to validate and expand the applications of its technology. Keywords: nanomedicine, hafnium oxide, radiotherapy, solid tumors, oncology, NBTXR3, cancer treatment, nanoparticles, clinical trials, healthcare.

Valuation $2.02B

Revenue $42M

Total funding $50–100M

Power Law Unicorn$1–10B valuation tier Colt$25–100M revenue

Featured in

News Nanobiotix raises €85M in oversubscribed global offering May 21, 2026

Investors

9 investors on Nanobiotix's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 3 investors entered at this stage

Karista

Bpifrance

HealthCare Royalty

Series B+ 6 investors entered at this stage

Seventure Partners

OTC Asset Management

Crédit Mutuel Equity

European Investment Bank

HSBC

Johnson & Johnson Innovation

Global footprint

Where Nanobiotix has talent and traffic

Workforce by country

6 countries with
team presence

🇫🇷 France87.5%

🇺🇸 United States8.7%

🇵🇱 Poland1%

🇮🇱 Israel1%

🇨🇭 Switzerland1%

Top 5 of 6 shown

Web traffic by country

8.3K monthly visits
across markets

🇺🇸 United States39.8%

🇫🇷 France26.5%

🇬🇧 United Kingdom18.1%

🇳🇿 New Zealand7.2%

🇮🇳 India7.2%

Top 5 markets shown

Talent graph

The shape of Nanobiotix's talent

Dealroom maps Nanobiotix's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

5 standout operatorsDealroom-flagged across the org

2 AI specialistsincl. 1 core researchers

145 employees mappedperson by person

DimensionScore

AI Talentlive

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Nanobiotix's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$69M patent portfolio · 30 active families

Estimated portfolio value

$69M

3.4% of market cap · 11.5× smaller than top peer BioNTech ($788M)

30 active patent families

Where Nanobiotix innovates BiocompatibilityBiocompatible nanoparticlesBiological organismChemistryDrug compound

Where Nanobiotix concentrates vs peers

Each axis is a top-10 topic across Nanobiotix and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Nanobiotix

An AI-synthesized read of the highest-engagement posts about Nanobiotix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nanobiotix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles